share_log

Johnson & Johnson | 10-Q: Q1 2024 Earnings Report

Johnson & Johnson | 10-Q: Q1 2024 Earnings Report

強生 | 10-Q:2024財年一季報
美股sec公告 ·  05/01 07:14
Moomoo AI 已提取核心訊息
Johnson & Johnson (J&J) has reported a 2.3% increase in worldwide sales to $21.4 billion for the fiscal first quarter of 2024, compared to $20.9 billion in the same period last year. This growth includes a 3.9% operational growth and a 1.6% negative currency impact. U.S. sales rose by 7.8%, while international sales saw a 3.4% decrease, including a 0.3% operational decline and a 3.1% negative currency impact. The Innovative Medicine segment saw a 1.1% increase in sales to $13.6 billion, with operational growth of 2.5% offset by a 1.4% negative currency impact. The MedTech segment experienced a 4.5% increase in sales to $7.8 billion, with a 6.3% operational growth and a 1.8% negative currency impact. The company's earnings before taxes for the quarter were $3.7 billion, representing 17.4% of sales, a significant improvement from a loss of...Show More
Johnson & Johnson (J&J) has reported a 2.3% increase in worldwide sales to $21.4 billion for the fiscal first quarter of 2024, compared to $20.9 billion in the same period last year. This growth includes a 3.9% operational growth and a 1.6% negative currency impact. U.S. sales rose by 7.8%, while international sales saw a 3.4% decrease, including a 0.3% operational decline and a 3.1% negative currency impact. The Innovative Medicine segment saw a 1.1% increase in sales to $13.6 billion, with operational growth of 2.5% offset by a 1.4% negative currency impact. The MedTech segment experienced a 4.5% increase in sales to $7.8 billion, with a 6.3% operational growth and a 1.8% negative currency impact. The company's earnings before taxes for the quarter were $3.7 billion, representing 17.4% of sales, a significant improvement from a loss of $1.3 billion in the previous year. J&J's restructuring efforts in its Innovative Medicine and MedTech segments have led to pre-tax restructuring expenses of $144 million and $27 million, respectively, for the quarter. The company has also been involved in various patent infringement lawsuits and has entered into confidential settlement agreements in some cases. Additionally, J&J is cooperating with government investigations and inquiries, including those related to the 340B Drug Pricing Program and antitrust laws.
強生公司(Johnson & Johnson,簡稱 J&J)報告稱,2024財年第一季全球銷售額同比增長2.3%,達到214億美元,而去年同期爲209億美元。這種增長包括3.9%的運營增長和1.6%的負貨幣影響。美國銷售額上漲7.8%,而國際銷售額下降3.4%,其中運營下降了0.3%,負貨幣影響爲3.1%。創新藥品板塊銷售額增長1.1%,達到136億美元,運營增長2.5%,但受1.4%的負貨幣影響。MedTech板塊銷售額增長4.5%,達到78億美元,其中運營增長了6.3%,但負貨幣影響爲1.8%。本季度公司稅前收益爲37億美元,佔銷售額的17.4%,大幅改善了去年13億美元的損失。J&J在創新藥品和MedTech板塊的重組工作導致本季度前期重組費用分別爲1.44億美元和2700萬美元。該公司還涉及各種專利侵權訴訟,並在某些案件中達成了保密和解協議。此外,J&J正在配合政府的調查和查詢,包括與340億美元的藥品定價計劃和反壟斷法有關的事項。
強生公司(Johnson & Johnson,簡稱 J&J)報告稱,2024財年第一季全球銷售額同比增長2.3%,達到214億美元,而去年同期爲209億美元。這種增長包括3.9%的運營增長和1.6%的負貨幣影響。美國銷售額上漲7.8%,而國際銷售額下降3.4%,其中運營下降了0.3%,負貨幣影響爲3.1%。創新藥品板塊銷售額增長1.1%,達到136億美元,運營增長2.5%,但受1.4%的負貨幣影響。MedTech板塊銷售額增長4.5%,達到78億美元,其中運營增長了6.3%,但負貨幣影響爲1.8%。本季度公司稅前收益爲37億美元,佔銷售額的17.4%,大幅改善了去年13億美元的損失。J&J在創新藥品和MedTech板塊的重組工作導致本季度前期重組費用分別爲1.44億美元和2700萬美元。該公司還涉及各種專利侵權訴訟,並在某些案件中達成了保密和解協議。此外,J&J正在配合政府的調查和查詢,包括與340億美元的藥品定價計劃和反壟斷法有關的事項。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息